*Sponsored
Jeff Ackerman Announces His Next Potential Breakout Idea— Starting Tomorrow Morning, Monday, April 28, 2025.
Coverage Initiated: Mainz Biomed (NASDAQ: MYNZ)
(MYNZ) Comes Backed By Several Potential Catalysts Including:
In Just Eight Sessions Between April 4 And April 15, 2025, (MYNZ) Quietly Moved Approximately 33%, From $2.65 To $3.54.
This Past Friday, (MYNZ) Triggered 15 Bullish Signals On TradingView’s 15-Minute Technical Dashboard, Including the Momentum Indicator.
(MYNZ) Has Less Than 3M Shares Listed In Its Float—Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift.
Recently, A Biotech Analyst At Maxim Group Set A $14 Target On (MYNZ), Which Suggests Over 330% Upside Potential.
Make Sure You Take A Look at (MYNZ) Before Tomorrow Morning…
April 27, 2025
Dear Reader,
Innovation doesn't always arrive with noise and celebration.
Sometimes, it starts in silence—where real solutions are built far from the spotlight.
In a modest lab tucked away in Mainz, Germany, a quiet but powerful shift is underway.
Here, one company is rethinking how early detection can change outcomes—not with flashy devices or digital trends, but with precision, science, and practical solutions.
Mainz Biomed (NASDAQ: MYNZ) isn’t chasing the next app or consumer craze.
It’s focused on something far more vital: a simple, at-home diagnostic test aimed at catching colorectal cancer—still the second leading cause of cancer death worldwide—before it becomes deadly.
But its technology isn’t the only reason it’s attracting new attention.
With a market cap under $11M and a float of fewer than 3M shares, (MYNZ) remains sharply under the radar—an often overlooked setup that could amplify attention as momentum builds.
Companies this lean don’t often stay quiet for long—especially when momentum starts to build.
In just eight sessions, (MYNZ) quietly advanced approximately 33%, moving from $2.65 on April 4 to $3.54 by April 15.
As of now, it’s trending above two key moving averages: its 5-day at $3.19 and 20-day at $3.23.
With the 50-day at $4.34, the 100-day at $4.97, and the 200-day at $8.64, we’re keeping all eyes on what could be a developing technical situation.
On Friday, (MYNZ) triggered 15 bullish signals on TradingView’s 15-minute technical dashboard, including its momentum indicator.
Just days before, on April 17, biotech analyst Michael Okunewitch of Maxim Group set a $14 target—suggesting over 330% upside from Friday’s open of $3.24. |
Tidak ada komentar:
Posting Komentar